This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
antibody
product name :
Anti-Trastuzumab Antibodies
catalog :
TRB-Y7
quantity :
1 mg, 100 ug
price :
1980 USD, 300 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
product information
company name :
ACROBiosystems
product type :
Antibody
clonality :
monoclonal
catalog :
TRB-Y7
product name :
Anti-Trastuzumab Antibodies
quantity :
1 mg, 100 ug
price :
1980 USD, 300 USD
quantity & price :
$300/100ug,$1980/1mg (500ug × 2)
target :
Trastuzumab
host species :
Mouse
Research :
For Research Use Only
Source :
Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Trastuzumab F(ab') 2 .
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Anti-Trastuzumab Antibodies on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● 4-8℃ for 12 months in lyophilized state;
● -70℃ for 3 years under sterile conditions after reconstitution.
Background :
Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments